Any current/future new fundraising through debt or equity?

No major new debt fundraising is planned for the near future. The company has availed fresh term loans of INR 72.33 crores during the year primarily for capex. Long-term loans stood at INR 241.44 crores as of March 31, 2024, down slightly from last year. Working capital utilization increased due to higher inventory, standing at INR 804 crores as of March 31, 2024. No plans for equity fundraising or share buyback in the immediate future. Management intends to utilize internal accruals for any expansions or opportunities. Any major financial decisions including buyback will be considered after c

Any current/future capex/capital investment/strategic investment?

Marginal capex planned mainly for replacing old machinery and debottlenecking; no major capacity augmentation expected. INR 60 crores targeted for retrofitting at the Asmoli distillery unit, expected to be commissioned within the calendar year. Additional capex of INR 35 crores (±5 crores) projected for maintenance and replacing depreciated equipment during the off-season. Conversion of existing distillery into dual-feed (grains and molasses) expected with lower capex than INR 60 crores, eligible for government interest subvention. Grain-based ethanol facility expected to start in the current

Future growth expectations in sales/revenue/volumes?

Branded sugar business expected to grow at low double-digit rates (around 10-15%) organically due to premium pricing and improved distribution, though growth remains cautious and measured. Pharma-grade sugar segment is a long-term play, with anticipated double-digit volume growth; current volumes are modest (~25,000-30,000 tons expected this year). Institutional and pharma sugar sales are targeted to increase market share to about 20%+ in the current financial year, with ongoing efforts to expand. Overall sugar quotas for May and June expected to be 4-5% higher than last year, supporting incre

Future growth expectations in earnings/operating earnings/profits/EPS?

Dhampur Bio Organics Limited aims for steady growth, focusing on profitability and cautious expansion. Plans include increasing cane acreage, value addition, and by-product utilization (ethanol, grain-based ethanol, country liquor). Branded sugar is expected to grow in low double digits, with a 10-15% volume growth outlook. Pharma sugar (institutional sales) is seen as a high-margin, long-term growth segment with expected double-digit growth. Marginal capital expenditure planned mainly for maintenance and retrofitting, no major capacity expansion currently. ESG initiatives are expected to be c

Dhampur BioQ4 FY24Agricultural Food & other Products

Dhampur Bio Q4 FY24 Earnings Call Analysis

Revenue, margin, capex, fundraise and order book outlook from management commentary.

Price: ₹146.28P/E: 38.0Market Cap: ₹971 CrSector: Agricultural Food & other Products

Management growth scorecard

Revenue

Category 3

Margin

Category 3

Fundraise

N/A

Order

N/A

Capex

0 of 3 growth signals are positive — mixed outlook.

Full analysis

Revenue guidance

Category 3

Branded sugar business expected to grow at low double-digit rates (around 10-15%) organically due to premium pricing and improved distribution, though growth remains cautious and measured.
Pharma-grade sugar segment is a long-term play, with anticipated double-digit volume growth; current volumes are modest (~25,000-30,000 tons expected this year).
Institutional and pharma sugar sales are targeted to increase market share to about 20%+ in the current financial year, with ongoing efforts to expand.
Overall sugar quotas for May and June expected to be 4-5% higher than last year, supporting incremental volume growth.
Focus on prudent and cautious growth across all segments without major capacity expansions, relying instead on debottlenecking and efficiency improvements.
Ethanol business to benefit from diversification into grain-based production with expected steady margins, helping utilization and profitability.

Margin guidance

Category 3

Dhampur Bio Organics Limited aims for steady growth, focusing on profitability and cautious expansion.
Plans include increasing cane acreage, value addition, and by-product utilization (ethanol, grain-based ethanol, country liquor).
Branded sugar is expected to grow in low double digits, with a 10-15% volume growth outlook.
Pharma sugar (institutional sales) is seen as a high-margin, long-term growth segment with expected double-digit growth.
Marginal capital expenditure planned mainly for maintenance and retrofitting, no major capacity expansion currently.
ESG initiatives are expected to be cost-effective and support long-term sustainability and marketing.
Despite recent volatility and weather impacts reducing production, a recovery in cane availability and crushing expected.
Overall, cautious yet optimistic outlook on increasing earnings and profits through operational efficiency and growth in value-added segments.

See what Dhampur Bio management said on margin guidance — free account, 30 seconds.

Fundraise plans

No major new debt fundraising is planned for the near future.
The company has availed fresh term loans of INR 72.33 crores during the year primarily for capex.
Long-term loans stood at INR 241.44 crores as of March 31, 2024, down slightly from last year.
Working capital utilization increased due to higher inventory, standing at INR 804 crores as of March 31, 2024.
No plans for equity fundraising or share buyback in the immediate future.
Management intends to utilize internal accruals for any expansions or opportunities.
Any major financial decisions including buyback will be considered after cash realization and stable performance.

Order book

The provided transcript does not mention any details about the current or expected order book or pending orders for Dhampur Bio Organics Limited. There is no specific information or data regarding order backlog, pending orders, or future order inflows discussed in the Q4 FY24 and FY24 earnings conference call held on April 26, 2024. If you need details on order book or pending orders, it is recommended to refer to the company's formal quarterly/annual reports or direct communications that may specify such operational metrics.

See what Dhampur Bio management said on order book — free account, 30 seconds.

Capex plans

Marginal capex planned mainly for replacing old machinery and debottlenecking; no major capacity augmentation expected.
INR 60 crores targeted for retrofitting at the Asmoli distillery unit, expected to be commissioned within the calendar year.
Additional capex of INR 35 crores (±5 crores) projected for maintenance and replacing depreciated equipment during the off-season.
Conversion of existing distillery into dual-feed (grains and molasses) expected with lower capex than INR 60 crores, eligible for government interest subvention.
Grain-based ethanol facility expected to start in the current calendar year, capitalizing on local maize availability.
No immediate major capex or greenfield distillery investments planned; company is cautiously monitoring industry policies before further expansion.
Bio-organic chemicals, bio-CNG, and bio-fertilizers are being monitored, but no concrete plans or investment announced yet.

Track Dhampur Bio — get its next earnings analysis in your feed

How does Dhampur Bio rank vs peers in Agricultural Food & other Products?

Pro feature

ThisDhampur Bio

Rev 3Mar 3

See where Dhampur Bio sits in Agricultural Food & other ProductsSee which companies these are, and every other name in the sector.Open rankings

How does Dhampur Bio rank in Agricultural Food & other Products?

Compare Dhampur Bio against every Agricultural Food & other Products company (Q4 FY24) on revenue, margins and earnings-call signals.

View Agricultural Food & other Products leaderboard →

What Dhampur Bio's management said in earlier quarters

Earlier calls (8)

Others in Agricultural Food & other Products this season

M.V.K. Agro (Q2 FY27)
For the quarter ended September 30, 2026, MVK Agro Food Product Ltd reported revenue from operations of ₹6,145.91 lakhs, up from ₹4,215.70 lakhs in the same…
Gokul Refoils (Q2 FY27)
17,449.65 lakhs (approximately 16.4% growth) . Key results statement takeaways from Gokul Refoils and Solvent Ltd's Q2 FY27 results statement — and how it ranks
Patanjali Foods (Q2 FY27)
11,322.58 crores, up 15.55% YoY. Key results statement takeaways from Patanjali Foods Ltd's Q2 FY27 results statement — and how it ranks against sector peers.
GRM Overseas (Q2 FY27)
Q2 FY27 Revenue from Operations: ₹452.6 Cr, up 22% YoY from ₹372.4 Cr in Q2 FY26 (Page 8) . Key investor presentation takeaways from GRM Overseas Ltd's Q2 FY27

🔎 Who's planning the most growth?

Companies ranked by management's own guidance — revenue, margins, capex and order book, from every earnings call in India.

See rankings →

Dhampur Bio Q4 FY24 Earnings Call Analysis

Revenue guidance

Fundraise plans

Capex plans

How does Dhampur Bio rank in Agricultural Food & other Products?

Continue your research

What Dhampur Bio's management said in earlier quarters

Others in Agricultural Food & other Products this season